mRNA cancer vaccines expand beyond melanoma to lung and pancreatic cancer trials

Clinical trials investigating mRNA vaccines for lung and pancreatic cancers are underway as of September 19, 2026. This expansion follows the reported success of an experimental drug using messenger RNA to deliver personalized skin cancer vaccines. Researchers state that this breakthrough could herald a wave of new treatments leveraging mRNA technology to target a range of different cancers.

Melanoma vaccine trial success

• ▪Researchers state that the reported success of personalized skin cancer vaccines could herald a wave of new treatments using mRNA technology for a range of cancers.
• ▪An experimental drug using messenger RNA to deliver personalized skin cancer vaccines has reported success, according to researchers.